CD274 and neoplasm: Average tumor burden was also reduced by more than 50% with the combination of MSU42011 plus anti-PD1 vs. control (0.46 ± 0.07 mm3 vs. 1.02 ± 0.13 mm3, p = 0.0077) or anti-PDL1 (0.43 ± 0.06 mm3, p = 0.0042) vs. control.